With cancer research and treatment evolving so dramatically over the past 10 years, we’re left thinking what will the next 10 years bring? New approaches and approvals coupled with higher survival and even improved cure rates are reasons to be very encouraged. However, there is much more progress needed to bring survival rates to a level that society will begin to accept. One approach that may help and that is starting to gain some significant steam is CAR-T.
To gain more insight into what CAR-T therapy has in store for the future, Kineticos recently hosted a round table with 3 experts representing companies that are actively developing CAR-T therapies. Click here for a compressed and edited version of Are We Getting a Bargain?
- Shailesh Maingi, Founder and CEO, Kineticos
- Bill Farley, VP of Business and Corporate Development, Sorrento Therapeutics
- Anil Goyal, Chief Business Officer, MimiVax
- Michael Catelani, Chief Operating and Financial Officer, Anixa Biosciences